Noguez RA, Shveid GD, Villegas ODA, Villalobos PA, Serrano OJA, Olivares BGM, Lázaro LJM, Regalado PGO, Camacho LCP, García LEA, Campos ALD, Murrieta GH, Zentella DA, Gerson CR

Language: Spanish
References: 22
Page: 238-248
PDF size: 372.62 Kb.

ABSTRACT

Introduction: In patients with metastatic cancer, it is imperative to develop tools for choosing chemotherapy. Chemotherapy sensitivity studies take months, doing it from ascites fluid considerably reduces the needed time. Objective: To evaluate the chemotherapy sensitivity in primary cultures of malignant cells obtained from ascites in order to generate a personalized medicine tool. Material and methods: Clinical trial in patients with metastatic cancer and malignant ascites at the ABC Medical Center. Cell cultures were obtained from each patient and they were exposed to different chemotherapy's, according to the cell death percentage we evaluated the sensitivity. The concordance between progression to chemotherapy and its resistance in vitro was reported as: total, partial or null. Results: 24 patients were included. Most women 13 (54.1%), the mean age was 61 ± 16.1 years, 75% had ECOG 1-2, the lines treatment median was 2 (IQR 1-4). The primary tumors were pancreas 7 (29.1%), breast 6 (25%), colorectal 5 (20.8%), hepatocellular 3 (12.5%), cholangiocarcinoma 2 (8.3%), and peritoneum 1(4.1%). Cell culture was established in 20 samples (80%). Partial or total concordance was found in 11 patients (55%), according to primary tumor was 100% in peritoneum, 83% in pancreas, 60% in colorectal, 50% in cholangiocarcinoma, 25% in breast and 0% in hepatocellular. Conclusions: Culturing neoplastic cells from ascites and exposing them to chemotherapy is feasible and can be performed in two weeks. The concordance between in vitro chemotherapy resistance and clinical progression was notable in peritoneal, pancreatic, and colorectal cancer.

REFERENCES

1. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011; 331 (6024): 1559-1564.

2. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017; 109 (9): djx030.

3. National Comprehensive Cancer Network. [Internet]. [Consulted 01 May 2021]. Available in: https://www.nccn.org/professionals/physician_gls/default.aspx

4. European Society for Medical Oncology. [Internet]. [Consulted 01 May 2021]. Available in: https://www.esmo.org/Guidelines

5. Sangisetty SL, Miner TJ. Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg. 2012; 4 (4): 87-95.

6. Hodge C, Badgwell BD. Palliation of malignant ascites. J Surg Oncol. 2019; 120 (1): 67-73.

7. Liu F, Kong X, Dou Q, Ye J, Xu D, Shang H et al. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites. Ann Hepatol. 2014; 13 (3): 357-363.

8. Ayantunde AA, Parsons SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol. 2007; 18 (5): 945-949.

9. Sigman M. Introduction: personalized medicine: what is it and what are the challenges? Fertil Steril. 2018; 109 (6): 944-945.

10. Abe K, Wakatsuki T, Katsushima F, Monoe K, Kanno Y, Takahashi A et al. A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy. World J Gastroenterol. 2009; 15 (41): 5228-5231.

11. Dufrenoy J. Les méthodes auxanographiques et leur application au dosage des antibiotiques. Ann Parasitol Hum Comp. 1947; 22 (5-6): 449-479.

12. Shveid D. Caracterización y perfiles moleculares de células tumorales humanas derivadas de cáncer de mama en mujeres con obesidad (Tesis de Maestría). Ciudad de México. Universidad Anáhuac. 2017.

13. Badillo LE. Caracterización biológica de células de cáncer de mama derivadas de pacientes con obesidad. (Tesis de doctorado). Ciudad de México. Universidad Nacional Autónoma de México. 2018.

14. Thériault BL, Portelance L, Mes-Masson AM, Nachtigal MW. Establishment of Primary Cultures from Ovarian Tumor Tissue and Ascites Fluid, Chapter 24. Malek A. Ovarian Cancer: Methods and Protocols, Methods in Molecular Biology. United States. Springer Science. 2013.

15. Kar R, Chawla D, Gupta B, Mehndiratta M, Wadhwa N, Agarwal R. Establishment of primary cell culture from ascitic fluid and solid tumor obtained from epithelial ovarian carcinoma patients. Int J Gynecol Cancer. 2017; 27 (9): 2000-2005.

16. Li X, Zhu D, Li N, Yang H, Zhao Z, Li M. Characterization of ascites-derived tumor cells from an endometrial cancer patient. Cancer Sci. 2017; 108: 2352-2357.

17. Szulkin A, Otvos R, Hillerdal CO, Celep A, Yousef-Fadhel E, Skribek et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions. BMC Cancer. 2014; 14: 709.

18. Dawson TP, Iyer R V, Lea RW, Roberts P, Harris F, Ashton K et al. The MTS vs. the ATP assay for in vitro chemosensitivity testing of primary glioma tumour culture. Neuropathol Appl Neurobiol. 2010; 36 (6): 564-567.

19. Brigulová K, Cervinka M, Tosner J, Sedláková I. Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro. 2010; 24 (8): 2108-2115.

20. Fenizia F, Lambiase M, Aurisicchio L, Normanno N, Ciliberto G, Mancini R. Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. J Transl Med. 2016; 14: 61.

21. Akiyoshia T, Wada T, Nakamurab Y. Clinical correlations with chemosensitivities measured in a simplified tritiated thymidine incorporation assay in patients with malignant effusion. Oncology. 1990; 47: 418-421.

22. Tournigand C, André T, Achille E, Lleldo G, Flesh M, Mery-Mignard D et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22 (2): 229-237.

EVIDENCE LEVEL

III